Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 857 clinical trials
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

This is an open label investigator initiated Phase II study of single agent pembrolizumab (Keytruda) in metastatic HER2-receptive negative breast cancer patients with germline deletion in the

neutrophil count
stage iv breast cancer
pembrolizumab
hormone therapy
HER2
  • 0 views
  • 25 Jan, 2021
  • 2 locations
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

This study will evaluate the effectiveness and safety of intravenous injection of RC48-ADC in the treatment of HER2 expression (HER2 positive and HER2 low expression) gynecological malignancies

  • 1 views
  • 21 Mar, 2022
  • 1 location
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);

  • 0 views
  • 15 Oct, 2021
  • 1 location
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.

  • 0 views
  • 30 Jun, 2022
  • 47 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their

estrogen
aromatase inhibitor
HER2
cish
progesterone receptor
  • 39 views
  • 25 Mar, 2022
  • 38 locations
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer (PEER)

advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the final tolerability and preliminary

  • 2 views
  • 06 Feb, 2022
  • 1 location
Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT

Neoadjuvant chemotherapy (NACT) is standard treatment for many triple-negative (TNBC) and HER2-positive breast cancer. Study showed about half of the biopsy-proven axillary disease will be

  • 0 views
  • 05 May, 2022
  • 1 location
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

This study evaluates the efficacy and safety of SRT combined with pyrotinib and capecitabine in the treatment of patients with HER2-positive advanced breast cancer patients with brain metastases

  • 0 views
  • 15 Mar, 2022
  • 1 location
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the

  • 0 views
  • 07 Oct, 2022
  • 3 locations
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or

estrogen
bilateral breast cancer
thyroid-stimulating hormone
epidermal growth factor receptor
paclitaxel
  • 0 views
  • 19 Apr, 2022
  • 1 location